October 18, 2018 03:15 AM EDTUpdated 03:29 AM
Deals

From ze­ro to hero: En­do­cyte’s lit­tle deal a year ago spurred a come­back capped by $2.1B No­var­tis buy­out

John Carroll

Editor & Founder

A year ago, with its stock in the toi­let af­ter its lead drug flopped in Phase III, forc­ing a re­struc­tur­ing, new En­do­cyte CEO Mike Sher­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

Ed­i­tas to cut 65% of work­force, of­fi­cial­ly stops work on ex vi­vo sick­le cell ther­a­py

Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times